---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-067774"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:47:02.232569+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics updates on CAR T pipeline; shifts focus to CTX112/CTX131, CTX110 Part B shows 23% 6-month CR

## Summary
- Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.
- Emerging data show CTX112 and CTX131 achieve significantly higher CAR T expansion and functional persistence in patients vs. first-gen.
- CTX110 Phase 1/2 Part B reported increased 6-month complete response rate of 23%, up from 19% in Part A.
- Company will transition CTX110 and CTX130 patients to long-term follow-up; CTX112 and CTX131 trials ongoing.
- Internal GMP facility manufacturing CTX112 and CTX131 for clinical trials; manufacturing robustness improved.

## SEC filing metadata
- accession: 0000950170-23-067774
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/0000950170-23-067774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023067774/crsp-20231204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-067774
- JSON: https://secwatch.observer/filing/0000950170-23-067774.json
- Plain text: https://secwatch.observer/filing/0000950170-23-067774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.